Early Communication of an Ongoing Safety Review: Bisphosphonates FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER Early Communication of an Ongoing Safety Review
Bisphosphonates: Alendronate (Fosamax, Fosamax Plus D), Etidronate (Didronel), Ibandronate (Boniva), Pamidronate (Aredia), Risedronate (Actonel, Actonel W/Calcium), Tiludronate (Skelid), and Zoledronic acid This information reflects FDA’s current analysis of available data concerning these drugs. Posting this
information does not mean that FDA has concluded there is a causal relationship between the drug products and
the emerging safety issue. Nor does it mean that FDA is advising health care professionals to discontinue
prescribing these products. FDA is considering, but has not reached a conclusion about whether this information
warrants any regulatory action. FDA intends to update this document when additional information or analyses
become available.

Publications in a recent issue of The New England Journal of Medicine have raised the question about the association of atrial fibrillation with the use of bisphosphonates. FDA has reviewed some safety data and requested additional data to further evaluate the risk of atrial fibrillation in patients who take bisphosphonates. An article and an accompanying letter to the editor in the May 3, 2007, issue of The New England Journal of Medicine describe increased rates of serious atrial fibrillation (defined by the authors as life-threatening or resulting in hospitalization or disability) in two different studies of older women with osteoporosis treated with the bisphosphonates, Reclast and Fosamax. In both studies, more women who received one of the bisphosphonates (Reclast-1.3% or Fosamax-1.5%) reportedly developed serious atrial fibrillation as compared to women who received placebo (Reclast study-0.5%, Fosamax study-1.0%). In both studies, the rates of all atrial fibrillation (serious plus nonserious) were not significantly different between groups treated with bisphosphonate versus placebo. What does FDA know about this concern?
The FDA reviewed spontaneous post-marketing reports of atrial fibrillation reported in association with oral and intravenous bisphosphonates and did not identify a population of bisphosphonate users at increased risk of atrial fibrillation. In addition, as part of the data review for the recent approval of once-yearly Reclast for the treatment of postmenopausal osteoporosis, the FDA evaluated the possible association between atrial fibrillation and the use of Reclast. Most cases of atrial fibrillation occurred more than a month after drug infusion. Also, in a subset of Early Communication of an Ongoing Safety Review: Bisphosphonates patients monitored by electrocardiogram up to the 11th day following infusion, there was no significant difference in the prevalence of atrial fibrillation between patients who received Reclast and patients who received placebo. Atrial fibrillation is a heart rhythm disorder common in individuals 65 years old and older, the same age range of many of the patients studied in the article published in The New England Journal of Medicine. Upon initial review, it is unclear how these data on serious atrial fibrillation should be interpreted. Therefore, FDA does not believe that healthcare providers or patients should change either their prescribing practices or their use of bisphosphonates at this time. This early communication is in keeping with FDA’s commitment to inform the public about its ongoing safety reviews of drugs. FDA is seeking additional data to allow for an in-depth evaluation of the atrial fibrillation issue for the entire class of bisphosphonates. It may take up to 12 months to complete the evaluation at which time FDA will communicate the conclusions and any resulting recommendations to the public. Moreover, FDA is continuing to monitor spontaneous post-marketing reports of atrial fibrillation reported in patients who have taken bisphosphonates. Bisphosphonates are a class of drugs used primarily to increase bone mass and reduce the risk for fracture in patients with osteoporosis. Bisphosphonates are also used to slow bone turnover in patients with Paget’s disease of the bone and to treat bone metastases and lower elevated levels of blood calcium in patients with cancer. There are 7 FDA-approved bisphosphonates: alendronate (Fosamax, Fosamax Plus D), etidronate (Didronel), ibandronate (Boniva), pamidronate (Aredia), risedronate (Actonel, Actonel W/Calcium), tiludronate (Skelid), and zoledronic acid (Reclast, Zometa). The FDA urges both healthcare professionals and patients to report side effects from the use of bisphosphonates to the FDA's MedWatch Adverse Event Reporting program. z on-line at z by returning the postage-paid FDA form 3500 (available in PDF format at to 5600 Fishers Lane, Rockville, MD 20852-9787 z faxing the form to 1-800-FDA-0178 z by phone at 1-800-332-1088 PDF requires the free Adobe Acrobat Reader CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | Privacy | Accessibility | HHS Home Page FDA/Center for Drug Evaluation and Research


AXS TV Schedule for Mon. June 3, 2013 to Sun. June 9, 2013 Monday June 3, 2013 Rendezvous - Michael and Sara reunite, but their time together is cut short as Mahone finally Cindy Crawford’s supermodel secret to youthful, radiant-looking skin with Meaningful Beauty. catches up to them; on the road with LJ, Lincoln meets his father; and Bellick finally gets T-Bag to give up his secret .

SENAR - SERVIÇO NACIONAL DE APRENDIZAGEM RURAL 15/10/2009 Página: GERÊNCIA TÉCNICA RLMOD01 - RELAÇÃO DE CURSOS OFERECIDOS Descrição do Curso Min. Par. Max. Par. Importância e administração na unidade de produçãoImportância e administração dos recursos humanosImportância da área de comercialização e seu relacionamentoFunção da administraçãoImportân

Copyright © 2010-2014 Internet pdf articles